Almitas Capital LLC Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Almitas Capital LLC cut its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 45.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 752,003 shares of the company's stock after selling 632,526 shares during the quarter. Almitas Capital LLC owned approximately 0.89% of Atea Pharmaceuticals worth $2,519,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Atea Pharmaceuticals in the third quarter valued at approximately $99,000. Intech Investment Management LLC lifted its position in shares of Atea Pharmaceuticals by 236.0% in the 4th quarter. Intech Investment Management LLC now owns 35,989 shares of the company's stock worth $121,000 after purchasing an additional 25,278 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Atea Pharmaceuticals by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 45,391 shares of the company's stock valued at $152,000 after purchasing an additional 9,865 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Atea Pharmaceuticals during the fourth quarter worth $168,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Atea Pharmaceuticals by 5.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 73,883 shares of the company's stock worth $248,000 after buying an additional 3,882 shares during the last quarter. Institutional investors own 86.67% of the company's stock.

Atea Pharmaceuticals Trading Down 0.3 %

NASDAQ AVIR traded down $0.01 on Friday, hitting $2.98. 551,035 shares of the company were exchanged, compared to its average volume of 298,996. The company has a market cap of $254.86 million, a PE ratio of -1.44 and a beta of 0.17. The stock has a fifty day moving average of $2.95 and a 200-day moving average of $3.14. Atea Pharmaceuticals, Inc. has a 12 month low of $2.60 and a 12 month high of $4.15.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). On average, analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AVIR. Morgan Stanley decreased their price target on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. William Blair reiterated an "outperform" rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.